IP Library Granted Patent US 12,030,863
Granted Patent B2
US 12,030,863 · App. 17/516,865 · Granted Jul 9, 2024

Prodrugs of urolithins and uses thereof

Inventors: Christopher L. Rinsch (Lausanne, CH); Rune Andreas Ringom (Uppsala, CH)
Assignee: Amazentis SA
C07D311/80A61K31/366A61K31/4025A61K45/06C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,030,863
App. No.
17/516,865
Granted
Jul 9, 2024
Kind
B2
Abstract

The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR 1 ; each R 1 being independently H or C(═O)R 2 , and at least one R 1 group being C(═O)R 2 ; where each R 2 is selected from: CHR 3 NHR 4 , where R 4 is H and R 3 is a group selected from CH 3 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -3-(1H-indole), CH 2 CH 2 SCH 3 , CH 2 OH, CHOHCH 3 , CH 2 SH, CH 2 SeH and CH 2 PhpOH, wherein said R 3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 4 alkyl; or R 3 and R 4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 3 alkyl, wherein R A is C 1 -C 4 alkyl optionally substituted with one or more halogen, cyano or nitro groups. The compounds are effective pro-drugs for urolithins and they enable the ready delivery of urolithins to the site in the digestive tract where they can be absorbed into the body.

Claims (20)

1. A compound of formula (I) or a salt thereof:

wherein:

A, B, C, W, X and Y are H,

D and Z are independently OR 1 ;

each R 1 is independently C(═O)R 2 ;

each R 2 is independently selected from:

CHR 3 NHR 4 , where R 4 is H and R 3 is a group selected from CH 3 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -3-(1H-indole), CH 2 CH 2 SCH 3 , CH 2 OH, CHOHCH 3 , CH 2 SH, CH 2 SeH and CH 2 PhpOH,

wherein said R 3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 4 alkyl;

or R 3 and R 4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring,

wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 3 alkyl,

wherein R A is C 1 -C 4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.

2. The compound of claim 1 , wherein R 2 is CHR 3 NHR 4 , where R 4 is H and R 3 is selected from CH 3 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -3-(1H-indole), CH 2 CH 2 SCH 3 , CH 2 OH, CHOHCH 3 , CH 2 SH, CH 2 SeH and CH 2 PhpOH, wherein said R 3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, OR A or C 1 -C 4 alkyl.

3. The compound of claim 1 , wherein R 2 is CHR 3 NHR 4 , where R 4 is H and R 3 is selected from CH 3 , CH 2 CH(CH 3 ) 2 , and CH(CH 3 )CH 2 CH 3 , or R 3 and R 4 together with the C and N atoms to which they are attached form an unsubstituted 5-membered heteroalkyl ring.

4. The compound of claim 3 which is selected from:

5. A method for treating aging of the skin, comprising topically administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a salt thereof of claim 1 .

6. A composition, comprising a compound of formula (I) or a salt thereof of claim 1 ; and a carrier.

7. The composition of claim 6 , in the form of a solution or suspension.

8. The composition of claim 6 , in the form of a powder or granules suitable for dissolution or suspension in an aqueous medium.

9. The composition of claim 6 , further comprising a further active ingredient, wherein the further active ingredient is selected from rapamycin, resveratrol, metformin, and spermidine.

10. A food, beverage or dietary supplement comprising a compound of formula (I) or a salt thereof of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: RINSCH, CHRISTOPHER L.
To: AMAZENTIS SA
Reel/Frame 064707/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: RINGOM, RUNE ANDREAS
To: ONTARGET CHEMISTRY AB
Reel/Frame 064707/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: ONTARGET CHEMISTRY AB
To: AMAZENTIS SA
Reel/Frame 064729/0068 →
Priority Claims (1)
GB 1323008 · Dec 24, 2013 · national
Continuity (4)
Continuation 16741221 · Jan 13, 2020
Continuation 16005160 · Jun 11, 2018
Continuation 15107467
Related Publication 20220127240A1 · Apr 28, 2022
Cited By (3)
US 12,544,358 US 12,576,064 US 12,576,065